Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis

被引:0
|
作者
S. V. Ramagopalan
G. C. DeLuca
K. M. Morrison
B. M. Herrera
D. A. Dyment
M. R. Lincoln
S.-M. Orton
M. J. Chao
A. Degenhardt
M. Pugliatti
A. D. Sadovnick
S. Sotgiu
G. C. Ebers
机构
[1] Level 3,Dept. of Clinical Neurology, University of Oxford
[2] West Wing,Wellcome Trust Centre for Human Genetics
[3] John Radcliffe Hospital,Dept. of Medical Genetics and Faculty of Medicine
[4] University of Oxford,Institute of Clinical Neurology
[5] Division of Neurology,undefined
[6] University of British Columbia,undefined
[7] University of Sassari,undefined
来源
Journal of Neurology | 2008年 / 255卷
关键词
multiple sclerosis; genetics; outcome;
D O I
暂无
中图分类号
学科分类号
摘要
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system unsurpassed for its variability in disease outcome. As little is conclusively known about MS disease mechanisms, we have selected a variety of candidate genes that may influence the prognosis of the disease based on their function. A cohort of sporadic MS cases, taken from opposite extremes of the putative distribution of long-term outcome using the most stringent clinical criteria to date, was used to determine the role of on MS disease severity. The MS cases selected represent the prognostic best 5 % (benign MS) and worst 5 % (malignant MS) of cases in terms of clinical outcome assessed by the EDSS. Genotyping the two sets of MS patients (112 benign and 51 malignant) and a replication cohort from Sardinia provided no evidence to suggest that the genes selected have any outcome modifying activity, although small effects of these genes cannot be ruled out.
引用
收藏
相关论文
共 50 条
  • [41] Disease modifying treatments for multiple sclerosis - What is on the horizon?
    Weilbach, FX
    Gold, R
    CNS DRUGS, 1999, 11 (02) : 133 - 157
  • [42] Use of Disease-Modifying Drugs in Multiple Sclerosis
    Wurzius, F. Q.
    Silva, C. B.
    de Vecino, M. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 102 - 103
  • [43] Multiple Sclerosis, Disease-Modifying Therapies, and Infections
    Langer-Gould, Annette M.
    Smith, Jessica B.
    Gonzales, Edlin G.
    Piehl, Fredrik
    Li, Bonnie H.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (06):
  • [44] Multiple sclerosis disease modifying medicine utilisation in Australia
    Hollingworth, Samantha
    Walker, Kimitra
    Page, Andrew
    Eadie, Mervyn
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (12) : 2083 - 2087
  • [45] Oral Disease-Modifying Therapies for Multiple Sclerosis
    Kim, Woojun
    Zandona, Manuella Edler
    Kim, Su-Hyun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2015, 11 (01): : 9 - 19
  • [46] Adherence to Disease-Modifying Therapies for Multiple Sclerosis
    Higuera, Lucas
    Carlin, Caroline S.
    Anderson, Sarah
    Journal of Managed Care & Specialty Pharmacy, 2016, 22 (12): : 1394 - 1401
  • [47] The effect of disease modifying therapies on fatigue in multiple sclerosis
    Rivera, Samantha Cruz
    Aiyegbusi, Olalekan Lee
    Meier, Daniela Piani
    Dunne, Achille
    Harlow, Danielle E.
    Henke, Christian
    Kamudoni, Paul
    Calvert, Melanie
    QUALITY OF LIFE RESEARCH, 2024, 33 : S194 - S194
  • [48] Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
    Erin E. Longbrake
    Becky J. Parks
    Anne H. Cross
    Current Neurology and Neuroscience Reports, 2013, 13
  • [50] New and emerging disease modifying therapies for multiple sclerosis
    Saidha, Shiv
    Eckstein, Christopher
    Calabresi, Peter A.
    YEAR IN IMMUNOLOGY, 2012, 1247 : 117 - 137